JNJ Jan 2025 170.000 call
| Previous Close | 6.50 |
| Open | 5.15 |
| Bid | 5.50 |
| Ask | 5.65 |
| Strike | 170.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 4.91 - 5.50 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 11.79k |
PR NewswireDexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
Johnson & Johnson (NYSE:JNJ) today announced results from the open-label Phase 2 SKIPPirr study, which evaluated additional prophylactic strategies to reduce the incidence of infusion-related reactions (IRRs) with intravenous (IV) RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. The study, which included 40 patients, showed that prophylaxis with 8-mg
ZacksXencor Stock Gains 23% on Encouraging Pipeline Advancements
XNCR moves four new XmAb drug development programs for autoimmune diseases. It also provided favorable updates for two of its oncology drug candidates.
ZacksJohnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $166.61, moving +1.36% from the previous trading session.
